Opinion|Videos|January 24, 2025
Clinical Insights and Real-World Evidence
Panelists discuss, which patients are favored for the Venetoclax-Obinutuzumab treatment approach.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- In which patients would you favor the Venetoclax-Obinutuzumab treatment approach?
Advertisement
Related to this article
Matthew S. Davids, MD, MMSc, discusses data from BRUIN CLL-322 and how they may shake up the CLL treatment paradigm.
CHMP recommends pirtobrutinib for CLL across all treatment lines after phase 3 trials showed strong efficacy and a favorable safety profile.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Subcutaneous Isatuximab Delivered Via On-Body Delivery System for Multiple Myeloma
2
FDA Approves Pembrolizumab Plus Enfortumab Vedotin in MIBC
3
Risvutatug Rezetecan Shows OS Benefit Over Topotecan in Relapsed SCLC
4
FDA Flashback: Breast Cancer Decisions and News From June 2026
5